Our recent reports suggest that endogenous LPA agonist, cPA, which is a bona fide second messenger and a physiological inhibitor of PPARγ [15] has emerged as a potential therapeutic target in the treatment of colon cancer [16]. The gene discussed is PPARG; the disease is malignant colon neoplasm.